Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

NOBLE: T-817MA for Mild to Moderate Alzheimer's Disease

Start: March 2014
End: May 2017
Enrollment: 450

What Is This Study About?

This Phase II study will evaluate the efficacy of the experimental drug T-817MA as a possible treatment for people with mild to moderate Alzheimer's disease. Its impact on cognition and daily functioning will be measured by standard tests.

Do I Qualify To Participate in This Study?

Minimum Age: 55 Years

Maximum Age: 85 Years

Must have:

  • Diagnosis of mild to moderate Alzheimer's disease
  • Taking the medication donepezil (Aricept) or rivastigmine transdermal system (Exelon patch); memantine (Namenda) is allowed only when prescribed in combination with donepezil or the rivastigmine transdermal system
  • Living in the community
  • Study partner or caregiver who has regular contact with participant (at least 10 hours per week) and can accompany his/her to study visits
  • Participant and caregiver able to read and understand English
  • Female participants must be postmenopausal or surgically sterile

Must NOT have:

  • Clinically significant cardiac, hepatic, or renal impairment
  • Non-Alzheimer's dementia (for example, vascular dementia, frontotemporal disorder, Lewy body dementia)
  • Taking any drug for Alzheimer's disease other than donepezil or the rivastigmine transdermal system, including oral rivastigmine (Exelon) or galantamine (Razadyne)

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.


Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Toyama Chemical Co., Ltd.

Collaborator Sponsor

  • Alzheimer's Disease Cooperative Study (ADCS)

Source: ID: NCT02079909

An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health